United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd grew its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 300.7% during the 4th quarter, HoldingsChannel reports. The firm owned 2,693 shares of the biotechnology company’s stock after buying an additional 2,021 shares during the period. Harvest Fund Management Co. Ltd’s holdings in United Therapeutics were worth $949,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Xponance Inc. boosted its stake in United Therapeutics by 9.0% during the 4th quarter. Xponance Inc. now owns 7,350 shares of the biotechnology company’s stock worth $2,593,000 after purchasing an additional 605 shares during the last quarter. Generali Asset Management SPA SGR acquired a new stake in United Therapeutics during the 4th quarter worth $3,008,000. Thrivent Financial for Lutherans boosted its stake in United Therapeutics by 1,325.5% during the 4th quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company’s stock worth $72,085,000 after purchasing an additional 189,967 shares during the last quarter. Axxcess Wealth Management LLC boosted its stake in United Therapeutics by 12.3% during the 4th quarter. Axxcess Wealth Management LLC now owns 1,362 shares of the biotechnology company’s stock worth $481,000 after purchasing an additional 149 shares during the last quarter. Finally, Signaturefd LLC boosted its stake in United Therapeutics by 4.7% during the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 30 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $361.95, for a total transaction of $3,619,500.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $932,745.15. This represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nilda Mesa sold 255 shares of the business’s stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the sale, the director now owns 5,528 shares in the company, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 90,255 shares of company stock worth $32,614,521. Company insiders own 11.90% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 27th. UBS Group boosted their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Finally, HC Wainwright reissued a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a research report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Trading Down 1.6 %

Shares of UTHR opened at $313.60 on Friday. The firm has a market cap of $14.08 billion, a P/E ratio of 13.77, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 12-month low of $221.53 and a 12-month high of $417.82. The company’s 50-day moving average price is $346.14 and its 200 day moving average price is $357.34.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period in the previous year, the firm earned $4.36 EPS. Equities research analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.